No GLP-1 receptor agonist currently has FDA approval for treating binge eating disorder
Mechanistically, semaglutide was found to enhance autophagy, as indicated by increased expression of autophagy-related proteins such as LC3-II, Atg7, and Beclin-1, and decreased expression of p62
Visit our Medication Safety Information
doi: 10.1016/S0306-4522(96)00434-4 [DOI] [PubMed] [Google Scholar] 140
Generally, you may be a good candidate for GLP-1 therapy if: You have a body mass index (BMI) that falls within a certain range, typically 27 or higher with a weight-related health condition, or 30 or higher without one
Patients should be educated about red flag symptoms requiring immediate medical attention, including severe persistent abdominal pain (especially if radiating to the back, suggesting possible pancreatitis), right upper quadrant pain with fever or jaundice (potential gallbladder disease), inability to keep fluids down for more than 24 hours, syncope, chest pain, or difficulty breathing